| [1] |
Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
|
| [2] |
Torre L A, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2):87-108.
|
| [3] |
Moulton CA, Gu CS, Law CH, et al. Effect of PET before liver resection on surgical management for colorectal adenocarcinoma metastases: a randomized clinical trial[J]. JAMA, 2014, 311(18): 1863-1869.
|
| [4] |
Tomlinson JS, Jarnagin WR, Dematteo RP, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure[J]. J Clin Oncol, 2007, 25(29):4575-4580.
|
| [5] |
Viganò L, Russolillo N, Ferrero A, et al. Evolution of long-term outcome of liver resection for colorectal metastases: analysis of actual 5-year survival rates over two decades[J]. An Surg Oncol, 2012, 19(6):2035-2044.
|
| [6] |
Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic colorectal metastases[J]. Ann Surg, 2002, 235(6):759-766.
|
| [7] |
Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2013, 14(12):1208-1215.
|
| [8] |
Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases[J]. Ann Surg, 1999, 230(3):309-318.
|
| [9] |
Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer:a multifactorial model of 929 patients[J]. Ann Surg, 2008, 247(1): 125-135.
|
| [10] |
Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a proposal of a prognostic scoring system[J]. J Am Coll Surg, 1999, 189(3):291-299.
|
| [11] |
Malik HZ, Prasad KR, Halazun KJ, et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases[J]. Ann Surg, 2007, 246(5):806-814.
|
| [12] |
Nielsen K, Rolff HC, Eefsen RL, et al. The morphological growth patterns of colorectal liver metastases are prognostic for overall survival[J]. Mod Pathol, 2014, 27(12):1641-1648.
|
| [13] |
Yoo SW, Kim J, Chong A, et al. Metabolic tumor volume measured by F-18 FDG PET/CT can further stratify the prognosis of patients with stage IV non-small cell lung cancer[J]. Nucl Med Mol Imaging, 2012, 46(4):286-293.
|
| [14] |
Lee HS, Kim HO, Hong YS, et al. Prognostic value of metabolic parameters in patients with synchronous colorectal cancer liver metastasis following curative-intent colorectal and hepatic surgery[J]. J Nucl Med, 2014, 55(4):582-589.
|
| [15] |
Allen PJ, Kemeny N, Jarnagin W, et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases[J]. J Gastrointest Surg, 2003, 7(1):109-117.
|
| [16] |
Wang K, Liu W, Yan XL, et al. Long-term postoperative survival prediction in patients with colorectal liver metastasis[J]. Oncotarget, 2017, 8(45):79927-79934.
|
| [17] |
Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome[J]. Science, 2006, 313(5795):1960-1964.
|
| [18] |
Tanis E, Julié C, Emile JF, et al. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983[J]. Eur J Cancer, 2015, 51(17):2708-2717.
|
| [19] |
Berthel A, Zoernig I, Valous NA, et al. Detailed resolution analysis reveals spatial T cell heterogeneity in the invasive margin of colorectal cancer liver metastases associated with improved survival[J]. Oncoimmunology, 2017, 6(3):e1286436.
|
| [20] |
Tsilimigras DI, Ntanasis-Stathopoulos I, Bagante F, et al. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: a systematic review of the current evidence[J]. Surg Oncol, 2018, 27(2):280-288.
|
| [21] |
Hegewisch-Becker S, Nöpel-Dünnebacke S, Hinke A, et al. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial[J]. Eur J Cancer, 2018(101):105-113.
|
| [22] |
Passiglia F, Bronte G, Bazan V, et al. Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? a systematic review and meta-analysis[J]. Crit Rev Oncol Hematol, 2016(99):150-157.
|
| [23] |
Pitroda SP, Khodarev NN, Huang L, et al. Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis[J]. Nat Commun, 2018, 9(1):1793.
|
| [24] |
Balachandran VP, Arora A, Gönen M, et al. A validated prognostic multigene expression assay for overall survival in resected colorectal cancer liver metastases[J]. Clin Cancer Res, 2016, 22(10):2575-2582.
|